Breaking news

Cyprus Achieves Largest Debt Reduction in Eurozone

Cyprus made significant strides in reducing its government debt, with the debt-to-GDP ratio falling to 70.5% by the end of the second quarter of 2024, according to Eurostat. This represents the largest decrease in the eurozone, with a 2.1% drop from Q1 2024 and a notable 10% reduction from Q2 2023.

In contrast, both the eurozone and the EU saw slight increases in their debt-to-GDP ratios. The eurozone’s ratio increased to 88.1% (up from 87.8% in Q1 2024), and the EU’s rose to 81.5% (up from 81.3%).

Despite Cyprus’ success, some countries continue to struggle with high debt levels. Greece and Italy recorded the highest ratios at 163.6% and 137.0%, respectively. Meanwhile, Bulgaria and Estonia maintained the lowest ratios at 22.1% and 23.8%.

The eurozone’s government debt is largely composed of debt securities, accounting for 84% of the total, while intergovernmental lending made up 1.5% of GDP.

Cyprus’ impressive debt reduction stands in contrast to the increases seen in countries such as Finland and Austria, demonstrating the country’s effective fiscal management amid global economic pressures.

Novo Partners With Anthropic To Accelerate AI-Driven Drug Development

Danish pharmaceutical group Novo, formerly Novo Nordisk and best known for Ozempic, has partnered with Anthropic to accelerate drug development using artificial intelligence.

AI Expands Into Novo’s R&D

Under the agreement, Novo will use Anthropic’s models and Claude Science across its research and development operations. The company said the tools will support scientific reasoning, improve productivity and help researchers explore new approaches to understanding human biology and drug mechanisms.

“Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,” Novo President and CEO Mike Doustdar said in a press release.

Anthropic CEO Dario Amodei said access to advanced AI models could help researchers shorten research timelines and improve drug discovery.

Novo Builds A Broader AI Strategy

The Anthropic partnership follows Novo’s separate agreement with OpenAI in April to use AI for analyzing complex datasets, identifying potential drugs and reducing the time between research and patient access.

Novo is also involved in Denmark’s AI infrastructure. In 2024, the Novo Nordisk Foundation partnered with Nvidia and the Export and Investment Fund of Denmark to establish the Danish Centre for AI Innovation, which operates the Gefion supercomputer.

Anthropic Expands In Life Sciences

Anthropic has also been expanding its presence in healthcare and pharmaceuticals. In May 2026, it announced a collaboration with Bristol Myers Squibb covering research, clinical development, manufacturing, commercial and corporate functions.

The Novo partnership adds another major pharmaceutical company to Anthropic’s life sciences business as drugmakers increasingly apply AI to research and development.

Aretilaw firm
eCredo
Uol
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter